Cantor Fitzgerald analyst Craig Bijou initiated coverage of RTI Surgical Holdings with an Overweight rating and $7 price target. New management over the last two years has transitioned the company focus to higher growth novel therapies in spine through several acquisitions and licensing deals, Bijou tells investors in a research note. The analyst believes RTI's "new differentiated" spine products will become the "growth engine" for the company, supported by its "profitable" OEM business. He sees a "disconnect" between RTI's current valuation given the potential for growth in its spine business.